This is in agreement with the literature, describing a higher frequency of PIK3CA mutations in squamous cell carcinomas (7.1–8.9%) than adenocarcinomas (0.9–2.9%).46, 47 Also, PTEN mutations are more frequently observed in squamous cell carcinomas (10.7%) than adenocarcinomas (1.7%).47 The prevalence of AKT1 mutation is low, but related to squamous cell histology.48 These mutations could regulate metabolism through PI3K/AKT signaling in a few squamous cell NSCLC. The gene discussed is PTEN; the disease is adenocarcinoma.